COMP <GO>
EBS vs LLY // OPERATING MARGIN
Emergent BioSolutions Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: EBS 2
— LLY 10
▲ OPERATING MARGIN LEADER: LLY
LAST: $7.22 (+1.83%) • MKT CAP: $370.2M
operating-margins
13.50%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
operating-margins
40.21%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EBS VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EBS | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.10% | 83.64% | -27.54 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.90% | 32.36% | -23.46 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.6x | 36.4x | -29.82 | EBS | /valuation <GO> |
| Free Cash Flow Yield | — | 2.30% | — | TIE | /fcf-yield <GO> |
| Operating Margin ACTIVE | 13.50% | 40.21% | -26.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | 7.10% | 31.90% | -24.80 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -28.80% | 45.51% | -74.31 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.41 | 9.29 | -7.88 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.0 | 66.6 | -13.62 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.5x | 26.3x | -19.75 | EBS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $370.2M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EBS REV | LLY REV | EBS GROSS % | LLY GROSS % | EBS FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $742.9M | $65.18B | 56.1% | 83.0% | $156.8M | $16.81B |
| FY 2024 | $1.04B | $45.04B | 34.7% | 81.3% | $35.8M | $8.82B |
| FY 2023 | $1.05B | $34.12B | — | 79.3% | -$206.3M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EBS // BETA —
LLY // BETA 0.51